Ormerod 1997.

Methods	DESIGN Within‐patient Participant delivery ALLOCATION Random Method of randomisation: not reported Concealment: unclear BLINDING Double‐blind (participant/investigator) WITHDRAWAL/DROPOUT Not described
Participants	N: 12 Treatment duration: 2 wks; FU: 2 wks LF: unclear BC: unclear Age: not reported Gender (per cent men): not reported Severity: TSS (0 to 24) =12.2 INCLUSION CRITERIA Bilaterally similar chronic Stable plaque psoriasis. EXCLUSION CRITERIA Recent systemic or UV therapy
Interventions	Betamethasone valerate ointment 0.1% BD (B) White soft paraffin BD (P)
Outcomes	Signs (erythema; elevation; scaling) Total Sign Score (0 to 24)
Notes	Wyeth‐Ayerst Research and Glaxo Dermatology sponsored the trial.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	The trial reported insufficient details.
Blinding (performance bias and detection bias) All outcomes	Low risk	The trial was double‐blind (participant/investigator).
Randomisation method reported	Unclear risk	The trial did not report this.
Loss to follow up	Unclear risk	The trial did not report this.
Baseline assessments	Low risk	These were partially done.
Baseline comparability demonstrated	Unclear risk	The trial did not report this.